Neogen (NEOG)
(Delayed Data from NSDQ)
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.44 USD
+0.16 (1.12%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $14.45 +0.01 (0.07%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Zacks News
DaVita (DVA) Partners with Epic to Launch EHR for Patients
by Zacks Equity Research
DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.
Can Neogen (NEOG) Stock Continue to Grow Earnings?
by Zacks Equity Research
Neogen (NEOG) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments in Q2.
Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Neogen (NEOG) rides high on balanced growth across all business segments.
Neogen Introduces Test for Listeria in Environmental Samples
by Zacks Equity Research
Neogen Corporation (NEOG) recently developed Listeria Right Now test system.
Neogen Offers NeoSeek Genomic Services to Ensure Food Safety
by Zacks Equity Research
Headquartered in Lansing, MI, Neogen Corporation (NEOG) recently announced the availability of next generation sequencing services for the food industry.
Neogen (NEOG) Earnings and Revenues Meet Estimates in Q3
by Zacks Equity Research
Neogen Corp (NEOG) reported adjusted earnings of 27 cents per share in the third quarter of fiscal 2017. The figure was in line with the Zacks Consensus Estimate and increased 22.7% from the year-ago quarter.
Medtronic Initiates BTK Study on DCB for PAD Cure in Europe
by Zacks Equity Research
Medtronic plc (MDT) recently initiated the IN.PACT below-the-knee (BTK) study to evaluate the effectiveness of a drug-coated balloon for treatment of peripheral arterial disease (PAD).
VWR Corporation (VWR): Q4 Lacks Shine, Currency Woes Remain
by Zacks Equity Research
On Mar 9, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR) -- a global provider of products, services and solutions to laboratory and production facilities.
Walgreens Boots Grapples with Headwinds: Should You Dump?
by Zacks Equity Research
On Mar 8, we issued an updated research report on Illinois-based leading pharmacy-led, health and wellbeing enterprise Walgreens Boots Alliance, Inc. (WBA).
CVS Health Adopts Epic EHR for Specialty Care Programs
by Zacks Equity Research
CVS Health Corporation (CVS) recently announced that it has chosen Epic as the electronic health record (EHR) system for CVS Specialty's care management programs.
BioScrip (BIOS): Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
BioScrip, Inc. (BIOS) reported net loss from continuing operations of $5.2 million or loss of 6 cents per share in the fourth quarter of 2016, much narrower than the year-ago net loss of $16.9 million or loss of 28 cents.
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay
by Zacks Equity Research
On Mar 02, we issued an updated research report on renowned home health and hospice services provider Amedisys Inc. (AMED).
VWR Corp Poised on Strong Earnings Amid Currency Headwinds
by Zacks Equity Research
On Feb 28, we issued an updated research report on VWR Corporation (VWR), an independent worldwide provider of products, services and solutions to laboratory and production facilities.
Baxter Partners ScinoPharm, Expands in Generic Injectables
by Zacks Equity Research
Baxter International Inc. (BAX) has formed a strategic partnership with Taiwan-based process R&D and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd.
Hill-Rom Holdings Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc.(HRC) scaled a new 52-week high of $67.44 on Mar 1, eventually closing a tad lower at $67.21.
Amedisys Buys 6 Home Health, Hospice Care Centers from Tenet
by Zacks Equity Research
Amedisys Inc. (AMED), a household name in home health and hospice services space, recently signed an exclusive agreement with Tenet Healthcare Corporation (THC).
Penumbra (PEN) Q4 Loss Narrower than Expected, Sales Top
by Zacks Equity Research
Penumbra, Inc. (PEN), that went public in Sep 2015, reported fourth-quarter 2016 loss of 8 cents per share, down from earnings of 5 cents per share year over year.
Mead Johnson Acquires Bega's Strategic Capabilities Business
by Zacks Equity Research
Mead Johnson Nutrition Company (MJN) recently inked an agreement with Bega Cheese Limited to acquire the latter's spray drying and finishing capabilities business in Australia.
Amedisys (AMED) Earnings Top Q4 Estimates, Revenues Lag
by Zacks Equity Research
Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 44 cents per share in the fourth quarter of 2016, up 10% year over year.
Medtronic (MDT) Presents 5-Year Cost Data of CRT Devices
by Zacks Equity Research
Medtronic plc (MDT) recently presented a five-year data report on cardiac resynchronization therapy (CRT) devices within its Cardiac Rhythm & Heart Failure (CRHF) division.
VWR Corporation (VWR) Tops Earnings in Q4; View Dull
by Zacks Equity Research
VWR Corporation (VWR) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 45 cents, reflecting a 4.3% decline from the year-ago quarter.
Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART) reported adjusted earnings per share of 52 cents in the fourth quarter of 2016, up 18% from the year-ago adjusted number.
Medtronic Poised on Strong Fundamentals Despite Several Woes
by Zacks Equity Research
On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).